Efficacy of Tele-CPASS Compared to In-person CPASS Therapy for Upper Extremity Motor Recovery

Recruiting now · Not applicable

Conditions studied: Stroke, Hemiparesis, Upper Extremity Impairments, Stroke Rehabilitation

In brief

This study evaluates whether a home-based telerehabilitation program (tele-CPASS) is as effective as an in-person rehabilitation program (CPASS) for improving arm and hand function after stroke. Stroke often leads to long-term difficulty using the affected arm in daily activities, and access to in-person therapy can be limited. This study aims to determine whether therapy delivered remotely can provide similar benefits to standard in-clinic care. Participants who recently experienced a stroke will be randomly assigned to receive 20 hours of upper extremity rehabilitation therapy either in person or through a telehealth platform. Both groups will receive the same type and amount of therapy focused on practicing meaningful, patient-selected daily activities. Participants will complete assessments before treatment, immediately after treatment, and at 6 and 12 months to measure recovery of arm function, real-world arm use, and participation in daily life. The results of this study will help determine whether telerehabilitation can improve access to effective stroke recovery interventions while maintaining clinical effectiveness comparable to in-person therapy.

Key facts

Study ID

NCT07661849

Run by

University of Texas, El Paso

People needed

42

Starts

2025-09-01

Expected to finish

2029-08-31

Last updated by the study team

2026-06-22

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 21 years or older
• Neuroimaging-confirmed stroke within 40 days prior to enrollment
• Persistent hemiparesis resulting in impaired upper extremity function, defined by a score of 0 to 3 on the NIH Stroke Scale motor arm item
• Able to participate in all study-related activities, including 1-year follow-up
• Short Blessed Memory Orientation and Concentration Scale score less than 8
• Able to follow 2-step commands
• Montreal Cognitive Assessment (MoCA) score greater than 25
• No upper extremity injury or condition that limited upper extremity use prior to the stroke

You may not qualify if…

• Inability to provide informed consent
• Persistent disabling neurologic condition, such as multiple sclerosis, Parkinsonism, amyotrophic lateral sclerosis, or dementia requiring medication
• Clinically significant fluctuations in mental status within 72 hours prior to randomization
• Active psychosis, psychosis within the prior 2 years, active substance abuse, or prior substance abuse
• Dense sensory loss, defined by a score of 3 or 4 on the NIH Stroke Scale sensory item
• Ataxia out of proportion to weakness in the affected arm, defined by a score greater than 1 on the NIH Stroke Scale ataxia item
• Not expected to survive 12 months because of other illnesses
• Pregnancy
• Severe aphasia
• Receipt of botulinum toxin or expectation of receiving botulinum toxin during the study period

Where it is running

• Rehabilitation Sciences Complex, University of Texas at El Paso, 3333 N Mesa St, El Paso, TX 79902 — El Paso, Texas, United States (enrolling)
• Texas Tech University Health Sciences Center El Paso - Neurology Clinic — El Paso, Texas, United States (enrolling)
• University Medical Center of El Paso - Rehabilitation Services — El Paso, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.